High-income settings
|
Cain, 2009, American Journal of Epidemiology |
Baltimore, Pittsburgh, Chicago and Los Angeles, US, MACS cohort |
1984a to April 2007 |
Entire period: 5.23/100 PY; Before 1996: 7.53/100 PY; After1996: 2.19/100 PY |
Patient inclusion criteria: no CD4 criteria, MSM only; Disease definition: CDC 1993, considers only the first ADI after cohort enrollment |
Mocroft, 1999, Journal of Acquired Immune Deficiency Syndromes |
London, UK, Royal Free Center for HIV Medicine |
1987a to 1998a
|
Before 1992: 27.4/100 PY; 1992-1993: 16.8/100 PY; 1994: 17.9/100 PY; 1995: 19.3/100 PY; 1996: 16.7/100 PY; 1997: 6.9/100 PY |
Patient inclusion criteria: no CD4 criteria; Disease definition: CDC 1993, considers only the first ADI after cohort enrollment |
San-Andres, 2003, Clinical Infectious Diseases |
Madrid, Spain, University Hospital |
January 1989-1997a
|
1989-1991: 36.4/100 PY; 1992: 43.2/100 PY; 1993: 39.0/100 PY; 1994: 32.4/100 PY; 1995: 32.0/100 PY; 1996: 30.9/100 PY; 1997: 14.6/100 PY |
Patient inclusion criteria: CD4 less than 500 cells/mm3or previous AIDS diagnosis; Disease definition: not clearly stated, likely considers all ADIb episodes after cohort enrollment |
Charurat, 2004, Journal of Women's Health |
4 states in US and Puerto Rico, WITS Cohort |
December 1989 to June 2002 |
Before Feb/1994: 4.52/100 PY; Mar/1994 to Jul/1996: 5.09/100 PY; After Aug/1996: 1.22/100 PY |
Patient inclusion criteria: no CD4 criteria, only women without previous diagnosis of AIDS; Disease definition: CDC 1993; considers only the first ADI after cohort enrollment |
Kaplan, 2000, Clinical Infectious Diseases |
10 US cities, Adults/Adolescents Spectrum of HIV Disease (ASD) Study |
1992a to September 1999 |
1996-1998: 16/100 PYc
|
Patient inclusion criteria: no CD4 criteria; Disease definition: not clearly stated, likely considers all ADId episodes after cohort enrollment |
Forrest, 1998, Clinical Infectious Diseases |
British Columbia, Canada, British Columbia Center for Excellence in HIV/AIDS |
January 1994 to December 1996 |
1994: 8/100 PY; 1996: 2.2/100 PY |
Patient inclusion criteria: no CD4 criteria, included only patients in use of antiretroviral drugs; Disease definition: CDC 1993; considers only the first ADI after cohort enrollment |
Mocroft, 2000, Lancet |
51 centers in Europe, Eurosida cohort |
May 1994 to spring 1999a
|
1994: 30.7/100 PY; 1998: 2.5/100 PYc
|
Patient inclusion criteria: CD4<500 cells/mm3; Disease definition: CDC 1993, considers the first ADI after cohort enrollment |
Buchacz, 2010, AIDS |
12 centers in US, HOPS cohort |
January 1994 to December 2007 |
1994-1997: 9.24/100 PY; 1998-2002: 2.96/100 PY; 2003-2007: 1.66/100 PY |
Patient inclusion criteria: no CD4 criteria; Disease definition: CDC 1993e; considers only the first ADI after cohort enrollment |
Ledergerber, 1999, Journal of the American Medical Association |
7 centers in Switzerland, Swiss HIV Cohort Study |
September 1995 to March 1999 |
Before to ART use: 15.1/100 PY; after ART use: 3.57/100 PY |
Patient inclusion criteria: no CD4 criteria, included patients who started ART between September 1995 and December 1997. Disease definition: CDC 1993, considers only the first ADI after cohort enrollment |
Wohl, 2003, Aids Patient Care and STDs |
10 US cities, ASD cohort |
1996a to 2000a
|
US born: 21.0/100 PY; Mexican born: 16.6/100 PY; Central American born: 13.9/100 PY |
Patient inclusion criteria: no CD4 criteria; included US born Latinos, Mexican born Latinos and Central American Latinos. Disease definition: not clear stated, apparently included all ADI presented in the study period. |
Plettenberg, 2011, Infection |
Germany, KompNet cohort |
1996a to 2010f
|
Group 1: 1.38/100 PY; Group 2: 0.78/100 PY |
Patient inclusion criteria: patients who started antiretroviral treatment.gDisease definition: included the first episode of an ADI after antiretroviral therapy. |
Low/middle-income settings
|
Fonseca, 1999, International Journal of Epidemiology |
São Paulo, Brazil, University of São Paulo |
1986a to June 1997 |
12.24/100 PY (converted from 10.2/1000 PM) |
Patient inclusion criteria: asymptomatic patients; Disease definition: CDC 1987, modified to include pulmonary tuberculosis as an AIDS defining-condition, considers only the first ADI after cohort enrollment |
Casseb, 2003, AIDS Patient care and STDs |
São Paulo, Brazil, University of São Paulo |
October 1987 to February 2002 |
4.6/100 PY (converted from 3.84/1000PM) |
Patient inclusion criteria: asymptomatic patients; Disease definition: CDC 1987, considers only the first ADI after cohort enrollment |
Badri, 2005, The Southern African Journal of HIV Medicine |
Cape Town, South Africa, Cape Town AIDS Cohort (CTAC) |
1992a to December 2000 |
21.34/100 PY |
Patient inclusion criteria: no CD4 criteria; Disease definition: WHO 1990, considers all ADI episodes after cohort enrollment |
Losina, 2007, Antiviral Therapy |
Abidjan, Ivory Coast, Cotrimo CI ANRS 059 and Cotrame ANRS1203 |
1996a to July 2003 |
Cotrimoxazole alone: CD4 less than 50 cells/mm3: 20.17/100 PY; CD4 above 200 cells/mm3: 3.54/100 PY; Cotrimoxazole plus ART (0-6 months): CD4 less 50 cells/mm3: 20.22/100 PY, CD4>200 cells/mm3: 2.79/100 PY; Cotrimoxazole plus ART (>6 months): CD4<50 cells/mm3: 6.84/100 PY, CD4>200 cells/mm3: 1.68/100 PY |
Patient inclusion: Patients participating in Cotrimo ANRS and Cotrame ANRS studies. Disease definition: considers only the first ADIhpresented in each periodi of study. Results were stratified by use of cotrimoxazole prophylaxis, ART and CD4 counts. |
Gadelha, 2002, Rev Inst Med Trop Sao Paulo |
Rio de Janeiro, Brazil, IPEC cohort |
September 1997 to December 1999 |
29/100 PYj
|
Patient inclusion criteria: at least one CD4<100 cells/mm3, included patients who started ART between September 1995 and December 1997. Disease definition: CDC 1993, considers the first ADI after cohort enrollment |
De Beaudrap, 2010, BMC Infectious Diseases |
Senegal, Initative Sénégalaise d'Acèss aux médicaments Antiretrovirauxk
|
August 1998 to April 2008 |
First year after ART initiation: 20.5/100 PY. Over the fourth year after ART initiation: 4.3/100 PY |
Patient inclusion criteria: no CD4 criteria. Disease definition: CDC 1993, considered the first episode of each ADI presented after ART initiation. Results were stratified by timing of ART use |
Podlasin, 2006, Infection |
10 centers in Poland |
2000a to 2002a
|
Total: 2.4/100 PY; 2000: 6.8/100 PY; 2001: 6.5/100 PY; 2002: 4.8/100 PY |
Patient inclusion criteria: none; Disease definition: CDC 1993, not clearly stated, likely considers all ADI after cohort enrollment |
Rojanawiwat, 2011, International Health |
Lampang, Thailand, Governmental Referral Hospitall
|
July 2000 to October 2004 |
Prior to ART: 19.1/100 PY; After ART use: 8.2/100 PY |
Patient inclusion criteria: no CD4 criteria; Disease definition: included the first episode of all ADImpresented by the patient |